Veeva Data Cloud Presentation

FY 2022 Guidance Total Revenue Subscription Revenue Commercial Subscription Revenue¹ R&D Subscription Revenue¹ Services Revenue Non-GAAP Operating Income Non-GAAP Fully Diluted Net Income per Share Calculated Billings Cash from Operations (excluding ETB) Guidance $1,830-1,835 million ~$1,475 million ~$865 million ~$610 million $355-360 million ~$730 million ~$3.57 ~$1,940 million ~$710 million 1 As of October 28, 2021, revenue reporting will be broken out between Commercial Solutions and R&D Solutions. This realignment is consistent with how we manage the business, with all of our Commercial solutions now reported as Commercial Solutions Revenue. We will report our Vault Commercial Content offerings, which includes PromoMats and MedComms, in our Commercial Solutions revenue. R&D Solutions will include our Clinical, Regulatory, Quality, Safety, and CP&C suites of products. For FY22, this realignment moves roughly $165 million of subscription revenue related to PromoMats and MedComms to be included in Commercial. On a realigned basis, our FY22 guidance for Commercial subscription revenue is roughly $865 million and R&D subscription revenue is roughly $610 million. Guidance issued on October 28, 2021. We are not able, at this time, to provide GAAP targets for operating income and fully diluted net income per share for the fiscal year ending January 31, 2022 because of the difficulty of estimating certain items excluded from non-GAAP operating income and non-GAAP fully diluted net income per share that cannot be reasonably predicted, such as charges related to stock-based compensation expense. The effect of these excluded items may be significant. Copyright Veeva Systems 2021

View entire presentation